Lanifibranor

Cat. No.: 0225LY-0851

Purity: ≥95%

Identity: Confirmed by NMR.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Lanifibranor is a pan-PPAR agonist that activates the human alpha, sigma, and gamma subtypes with EC50 values of 1.5 μM, 0.87 μM, and 0.21 μM, respectively.

Synonym: IVA337; 927961-18-0; IVA-337; Libfranor; 1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid; 5-Chloro-1-((6-benzothiazolyl)sulfonyl)-1H-indole-2-butanoic acid; 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid; 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; 4-(1-(1,3-benzothiazole-6-sulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; 4-[1-(1,3-benzothiazole-6-sulfonyl)-5-chloro-1H-indol-2-yl]butanoic acid

CAS No.: 927961-18-0

Compound CID: 68677842

Formula: C₁₉H₁₅ClN₂O₄S₂

Formula Weight: 434.92

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Lanifibranor can be used in fibrosis research to investigate the therapeutic effects of pan-PPAR agonism in systemic sclerosis and NASH.